Switch to:
Also traded in: Germany, Mexico, Spain, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
GRFS's Cash-to-Debt is ranked higher than
89% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. GRFS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GRFS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.25 Max: No Debt
Current: No Debt
Equity-to-Asset 0.33
GRFS's Equity-to-Asset is ranked lower than
81% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GRFS: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
GRFS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.33 Max: 0.37
Current: 0.33
0.28
0.37
Interest Coverage 3.89
GRFS's Interest Coverage is ranked lower than
92% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GRFS: 3.89 )
Ranked among companies with meaningful Interest Coverage only.
GRFS' s Interest Coverage Range Over the Past 10 Years
Min: 1.56  Med: 4.15 Max: 18.28
Current: 3.89
1.56
18.28
Piotroski F-Score: 7
Altman Z-Score: 2.03
Beneish M-Score: -1.90
WACC vs ROIC
5.00%
13.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 23.13
GRFS's Operating Margin % is ranked higher than
87% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. GRFS: 23.13 )
Ranked among companies with meaningful Operating Margin % only.
GRFS' s Operating Margin % Range Over the Past 10 Years
Min: 15.53  Med: 24.74 Max: 26.85
Current: 23.13
15.53
26.85
Net Margin % 13.35
GRFS's Net Margin % is ranked higher than
84% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. GRFS: 13.35 )
Ranked among companies with meaningful Net Margin % only.
GRFS' s Net Margin % Range Over the Past 10 Years
Min: 2.8  Med: 13.04 Max: 16.2
Current: 13.35
2.8
16.2
ROE % 15.60
GRFS's ROE % is ranked higher than
91% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. GRFS: 15.60 )
Ranked among companies with meaningful ROE % only.
GRFS' s ROE % Range Over the Past 10 Years
Min: 4.27  Med: 18.11 Max: 28.28
Current: 15.6
4.27
28.28
ROA % 5.52
GRFS's ROA % is ranked higher than
86% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. GRFS: 5.52 )
Ranked among companies with meaningful ROA % only.
GRFS' s ROA % Range Over the Past 10 Years
Min: 1.34  Med: 6.27 Max: 11.48
Current: 5.52
1.34
11.48
ROC (Joel Greenblatt) % 32.16
GRFS's ROC (Joel Greenblatt) % is ranked higher than
88% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. GRFS: 32.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GRFS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.67  Med: 30.3 Max: 41.3
Current: 32.16
17.67
41.3
3-Year Revenue Growth Rate 13.70
GRFS's 3-Year Revenue Growth Rate is ranked higher than
64% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. GRFS: 13.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GRFS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 7.7  Med: 14.6 Max: 28.2
Current: 13.7
7.7
28.2
3-Year EBITDA Growth Rate 10.40
GRFS's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. GRFS: 10.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GRFS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 8.2  Med: 28.9 Max: 38.4
Current: 10.4
8.2
38.4
3-Year EPS without NRI Growth Rate 16.20
GRFS's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. GRFS: 16.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GRFS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -31.6  Med: 27.7 Max: 105.1
Current: 16.2
-31.6
105.1
GuruFocus has detected 4 Warning Signs with Grifols SA $GRFS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GRFS's 30-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

GRFS Guru Trades in Q2 2016

Ron Baron 75,000 sh (unchged)
Jim Simons Sold Out
Mario Gabelli 55,800 sh (-2.79%)
John Paulson 7,345,166 sh (-58.11%)
» More
Q3 2016

GRFS Guru Trades in Q3 2016

Jim Simons 28,804 sh (New)
Ron Baron 75,000 sh (unchged)
Mario Gabelli 40,625 sh (-27.20%)
John Paulson 2,478,600 sh (-66.26%)
» More
Q4 2016

GRFS Guru Trades in Q4 2016

Jim Simons Sold Out
John Paulson Sold Out
Mario Gabelli 30,000 sh (-26.15%)
Ron Baron 40,000 sh (-46.67%)
» More
Q1 2017

GRFS Guru Trades in Q1 2017

Jim Simons 235,204 sh (New)
Ron Baron 40,000 sh (unchged)
Mario Gabelli 30,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GRFS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412 
Compare:NAS:BMRN, OTCPK:NVZMF, NAS:ALXN, OTCPK:UCBJY, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:TSRO, NAS:INCY, NAS:BIVV, OTCPK:ALIOY, NAS:IONS, NAS:ALNY, NAS:EXEL, NAS:UTHR, NAS:VRTX, NAS:ARIA, NAS:GLPG, NAS:TECH » details
Traded in other countries:G0FB.Germany, GRFPN.Mexico, GRF.P.Spain, 0RDU.UK, GIKLY.USA,
Headquarter Location:Spain
Grifols SA is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. It operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials.

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 90% of sales in 2013. Grifols also has smaller segments including diagnostics, hospital supplies, and raw materials, but diagnostics grew to almost 20% of revenue in 2014 with the acquisition of Novartis' diagnostics unit.

Ratios

vs
industry
vs
history
PE Ratio 29.99
GRFS's PE Ratio is ranked higher than
50% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. GRFS: 29.99 )
Ranked among companies with meaningful PE Ratio only.
GRFS' s PE Ratio Range Over the Past 10 Years
Min: 21.8  Med: 33.12 Max: 96.2
Current: 29.99
21.8
96.2
Forward PE Ratio 23.09
GRFS's Forward PE Ratio is ranked lower than
60% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. GRFS: 23.09 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 29.99
GRFS's PE Ratio without NRI is ranked higher than
51% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. GRFS: 29.99 )
Ranked among companies with meaningful PE Ratio without NRI only.
GRFS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 21.72  Med: 31.81 Max: 97.1
Current: 29.99
21.72
97.1
Price-to-Owner-Earnings 33.45
GRFS's Price-to-Owner-Earnings is ranked lower than
61% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. GRFS: 33.45 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GRFS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.11  Med: 32.42 Max: 47.23
Current: 33.45
18.11
47.23
PB Ratio 4.38
GRFS's PB Ratio is ranked lower than
55% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. GRFS: 4.38 )
Ranked among companies with meaningful PB Ratio only.
GRFS' s PB Ratio Range Over the Past 10 Years
Min: 2.32  Med: 4.18 Max: 6.76
Current: 4.38
2.32
6.76
PS Ratio 4.04
GRFS's PS Ratio is ranked higher than
76% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. GRFS: 4.04 )
Ranked among companies with meaningful PS Ratio only.
GRFS' s PS Ratio Range Over the Past 10 Years
Min: 1.95  Med: 3.55 Max: 12.85
Current: 4.04
1.95
12.85
Price-to-Free-Cash-Flow 48.80
GRFS's Price-to-Free-Cash-Flow is ranked lower than
74% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. GRFS: 48.80 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GRFS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.6  Med: 30.89 Max: 121.38
Current: 48.8
15.6
121.38
Price-to-Operating-Cash-Flow 26.20
GRFS's Price-to-Operating-Cash-Flow is ranked lower than
62% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. GRFS: 26.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GRFS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.02  Med: 18.97 Max: 169.33
Current: 26.2
11.02
169.33
EV-to-EBIT 15.40
GRFS's EV-to-EBIT is ranked higher than
87% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. GRFS: 15.40 )
Ranked among companies with meaningful EV-to-EBIT only.
GRFS' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.7  Med: 19.9 Max: 45.1
Current: 15.4
12.7
45.1
EV-to-EBITDA 12.70
GRFS's EV-to-EBITDA is ranked higher than
89% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. GRFS: 12.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
GRFS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.3  Med: 16.1 Max: 37.1
Current: 12.7
10.3
37.1
PEG Ratio 1.44
GRFS's PEG Ratio is ranked higher than
63% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. GRFS: 1.44 )
Ranked among companies with meaningful PEG Ratio only.
GRFS' s PEG Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.96 Max: 1.67
Current: 1.44
0.55
1.67
Current Ratio 3.12
GRFS's Current Ratio is ranked lower than
63% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. GRFS: 3.12 )
Ranked among companies with meaningful Current Ratio only.
GRFS' s Current Ratio Range Over the Past 10 Years
Min: 2.19  Med: 2.99 Max: 3.31
Current: 3.12
2.19
3.31
Quick Ratio 1.34
GRFS's Quick Ratio is ranked lower than
77% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GRFS: 1.34 )
Ranked among companies with meaningful Quick Ratio only.
GRFS' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.46 Max: 1.88
Current: 1.34
1.15
1.88
Days Inventory 263.77
GRFS's Days Inventory is ranked lower than
81% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. GRFS: 263.77 )
Ranked among companies with meaningful Days Inventory only.
GRFS' s Days Inventory Range Over the Past 10 Years
Min: 235.92  Med: 290.24 Max: 909.7
Current: 263.77
235.92
909.7
Days Sales Outstanding 42.65
GRFS's Days Sales Outstanding is ranked higher than
73% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. GRFS: 42.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
GRFS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.62  Med: 68.57 Max: 90.49
Current: 42.65
33.62
90.49
Days Payable 77.46
GRFS's Days Payable is ranked higher than
59% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. GRFS: 77.46 )
Ranked among companies with meaningful Days Payable only.
GRFS' s Days Payable Range Over the Past 10 Years
Min: 64.56  Med: 101.37 Max: 256.52
Current: 77.46
64.56
256.52

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.67
GRFS's Dividend Yield % is ranked higher than
69% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. GRFS: 1.67 )
Ranked among companies with meaningful Dividend Yield % only.
GRFS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.38  Med: 1.24 Max: 1.79
Current: 1.67
0.38
1.79
Dividend Payout Ratio 0.40
GRFS's Dividend Payout Ratio is ranked higher than
82% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. GRFS: 0.40 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GRFS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.26 Max: 0.56
Current: 0.4
0.14
0.56
3-Year Dividend Growth Rate 46.30
GRFS's 3-Year Dividend Growth Rate is ranked higher than
92% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. GRFS: 46.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GRFS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 46.3
Current: 46.3
0
46.3
Forward Dividend Yield % 1.81
GRFS's Forward Dividend Yield % is ranked higher than
75% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. GRFS: 1.81 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.67
GRFS's 5-Year Yield-on-Cost % is ranked higher than
64% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. GRFS: 1.67 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GRFS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.38  Med: 1.24 Max: 1.79
Current: 1.67
0.38
1.79
3-Year Average Share Buyback Ratio 0.20
GRFS's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. GRFS: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GRFS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -46.1  Med: -15.3 Max: 20.3
Current: 0.2
-46.1
20.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.08
GRFS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
65% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. GRFS: 2.08 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GRFS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.62  Med: 2.25 Max: 2.78
Current: 2.08
1.62
2.78
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.05
GRFS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
62% of the 24 Companies
in the Global Biotechnology industry.

( Industry Median: 1.21 vs. GRFS: 1.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.14
GRFS's Price-to-Median-PS-Value is ranked lower than
58% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. GRFS: 1.14 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GRFS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 0.99 Max: 3.27
Current: 1.14
0.59
3.27
Price-to-Peter-Lynch-Fair-Value 1.63
GRFS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
62% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. GRFS: 1.63 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GRFS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.95  Med: 1.04 Max: 1.51
Current: 1.63
0.95
1.51
Earnings Yield (Greenblatt) % 6.49
GRFS's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. GRFS: 6.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GRFS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 5 Max: 7.9
Current: 6.49
2.2
7.9
Forward Rate of Return (Yacktman) % 20.55
GRFS's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. GRFS: 20.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GRFS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 20.5  Med: 28.5 Max: 45.7
Current: 20.55
20.5
45.7

More Statistics

Revenue (TTM) (Mil) $4,532
EPS (TTM) $ 0.90
Beta1.28
Short Percentage of Float0.00%
52-Week Range $14.27 - 22.25
Shares Outstanding (Mil)682.82

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 4,753 5,035
EPS ($) 1.19 1.35
EPS without NRI ($) 1.19 1.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.80%
Dividends per Share ($) 0.45 0.51
» More Articles for GRFS

Headlines

Articles On GuruFocus.com
Investigational New Drug Application is Now Effective for Babesia Screening in Blood Donations Using May 09 2017 
Grifols Strengthens Position as Global Provider of Diagnostic Testing Solutions with Five-Year Exten Apr 24 2017 
Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Apr 17 2017 
Grifols 2016 Annual Report on Form 20-F filed with the SEC on April 4, 2017 Apr 04 2017 
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 

More From Other Websites
Hologic Smashes Fiscal Q2 Sales Views, Beats On Profit By 4 Cents May 10 2017
Investigational New Drug Application is Now Effective for Babesia Screening in Blood Donations Using... May 09 2017
VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y May 04 2017
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View Apr 27 2017
Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View Apr 27 2017
Grifols Strengthens Position as Global Provider of Diagnostic Testing Solutions with Five-Year... Apr 24 2017
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine Apr 20 2017
GENOCEA BIOSCIENCES (GNCA) Catches Eye: Stock Gains 7.1% Apr 20 2017
How to Uncover Institutional Buying Apr 19 2017
Can young blood pump new life into treatments for diseases of aging? Apr 19 2017
Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of... Apr 17 2017
Amgen Files for Xgeva Label Expansion, To Include Myeloma Apr 05 2017
Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk Apr 04 2017
Grifols 2016 Annual Report on Form 20-F filed with the SEC on April 4, 2017 Apr 04 2017
New Breakout Stocks Zacks Rank #1 (Strong Buy) Apr 01 2017
AbbVie's (ABBV) Humira Drug Label Update Approved by FDA Mar 31 2017
New Strong Buy Stocks for March 30th Mar 30 2017
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2% Mar 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)